Aktienanalyse zu Creative Medical Technology Holdings Inc (CELZ)CELZCreative Medical Technology Holdings Inc

Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company dedicated to the advancement of identifying and translating novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology and orthopedics. The Company conducts substantially all of its commercial operations through its subsidiary, Creative Medical Technologies, Inc. Its products include AlloStem (CELZ-201-DDT) - allogenic human perinatal tissue derived cell program (clinical phase), ImmCelz (CELZ-100) - personalized supercharged immune therapy platform (pre-clinical trials), Type I Diabetes (CELZ-201 CREATE-1) - type I diabetes, Allostemspine Chronic Lower Back Pain (CELZ 201 ADAPT), Alova, CaverStem - erectile dysfunction treatment, FemCelz - female sexual function treatment, StemSpine - regenerative stem cell procedure for the treatment of degenerative disc disease (clinical trials), and OvaStem - stem cell therapy for premature ovarian failure. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Creative Medical Technology Holdings Inc (CELZ) is currently not a strong buy due to its low price and high volatility, despite some positive catalysts. The stock is trading at $0.62, significantly down 68.47% year-to-date, and has an RSI of 34.445, indicating it may be oversold. However, the forward P/E ratio is at 0, and the company has a gross margin of -694.63%, which raises concerns about profitability. The main risk is the significant decline in stock value over the past year, with a 1-year change of -81.06%.